Overview of the 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure with Reduced Ejection Fraction

In the past four years since the publication of the 2017 American College of Cardiology (ACC) expert consensus decision pathway for optimization of heart failure with reduced ejection fraction (HFrEF)1, new therapies, trials and data have emerged in the treatment of patients with HFrEF. With this expansion of knowledge, the ACC has provided a 2021 update to include novel therapies, such as angiotensin receptor-neprilysin inhibitors (ARNIs), sodium-glucose cotransporter-2 inhibitors (SGLT2i) and percutaneous therapy for mitral regurgitation.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Editorial Source Type: research